WindRose Health Investors announced an investment in Avalon Healthcare Solutions, a Tampa-based company managing diagnostic test utilization for health plans. Founded in 2013, Avalon uses technology to control the costs of routine and genetic lab tests. New York-based WindRose, established in 2000, focuses on equity investments across the healthcare sector.

This deal highlights private equity's growing interest in healthcare technology that drives cost efficiency for insurers. Avalon's model addresses rising medical expenses by ensuring appropriate testing, a critical issue as diagnostic costs continue to climb. For investors, it signals confidence in platforms that can deliver savings and operational improvements for payers.

The transaction's value wasn't disclosed, but it follows a trend of PE firms backing companies that help health plans manage spending. Avalon’s role in overseeing genetic testing and routine diagnostics places it in a high-demand niche. Watch for further consolidation as more investors target healthcare's administrative and technology layers.